{"nctId":"NCT05364671","briefTitle":"Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients","startDateStruct":{"date":"2022-04-29","type":"ACTUAL"},"conditions":["Coronavirus Disease 2019 (COVID-19)"],"count":771,"armGroups":[{"label":"Raphamin","type":"EXPERIMENTAL","interventionNames":["Drug: Raphamin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Raphamin","otherNames":["MMH-407"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male and female patients aged 18-75 years old.\n2. Diagnosis of new coronavirus infection COVID-19 based on medical examination: axillary temperature \\>37.5°C, upper respiratory infection symptoms, SpO2 ≥ 95%, no symptoms of moderate or severe forms.\n3. The minimal baseline score for COVID-19-related symptoms defined as follows: at least two symptoms with a score of 2 or higher, with the exception of taste and smell where subjects may have a score of 1 or higher, and the absence of shortness of breath (difficulty breathing).\n4. Positive rapid test for for SARS-CoV-2 (COVID-19).\n5. The first 24 hours from the disease onset.\n6. Patients giving their consent to use reliable contraception during the study.\n7. Signed patient information sheet (informed consent form).\n\nExclusion Criteria:\n\n1. Moderate and severe COVID-19.\n2. The first four weeks after any vaccination/revaccination, including against COVID-19, influenza, pneumococcal and other infections.\n3. Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.).\n4. Patients requiring medications prohibited within the study.\n5. Medical history or previously diagnosed primary and secondary immunodeficiency.\n6. Medical history/suspicion of oncology of any localization (except for benign neoplasms).\n7. Exacerbation or decompensation of chronic diseases affecting the patient's ability to participate in the clinical study.\n8. Malabsorption syndrome, including congenital or acquired lactase or disaccharidase deficiency, galactosemia.\n9. Allergy/ hypersensitivity to any of the components of the medications used in the treatment.\n10. Pregnancy, breast-feeding; childbirth less than 3 months prior to the inclusion in the trial, unwillingness to use contraceptive methods during the trial.\n11. Use of medications listed in \"Prohibited concomitant therapy\" within 4 weeks before the study entry.\n12. Patients who, from the investigator's point of view, will fail to comply with the requirements of the trial or with the intake regimen of the study drugs.\n13. Medical history of mental diseases, alcoholism or drug abuse which, according to the investigator's opinion, will interfere with the study procedures.\n14. Participation in other clinical trials within 3 months prior to enrollment in this study.\n15. The patient is related to the study center staff directly involved in the trial or is the immediate relative of the investigator. Immediate family is defined as a spouse, parents, children or siblings, whether natural or adopted.\n16. The patient works for OOO \"NPF \"MATERIA MEDICA HOLDING\" i.e. is the company's employee, part-time employee under contract or appointed official in charge of the trial, or their immediate family.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With COVID-19 Progression to a More Severe Form","description":"Severity of COVID-19 is assessed in accordance with criteria presented in the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation \"Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)\".","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Sustained Clinical Recovery After New Coronavirus Disease COVID-19.","description":"Sustained clinical recovery is a sustained improvement of clinical symptoms for at least 4 consecutive days. The day of improvement is considered the first of these 4 days.\n\nCriteria for improvement of clinical symptoms (according to the scoring system \"Assessment of 14 Common COVID-19-Related Symptoms\") are defined as follows:\n\n* a score of 1 or 0 (for stuffy or runny nose, sore throat, low energy or tiredness, muscle or body aches, headache, chills or shivering, feeling hot or feverish, nausea, diarrhea);\n* a score 0 (for shortness of breath/difficulty breathing and vomiting);\n* a score no more than 2 (for cough);\n* no new symptoms with a score of 1 or 0;\n* axillary temperature ≤37.3°С.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":"2.4"},{"groupId":"OG001","value":"5.8","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Hospitalized Patients","description":"Based on the medical records.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to COVID-19 Progression to a More Severe Form","description":"Severity of COVID-19 will be assessed in accordance with the criteria presented in the current edition of the clinical recommendations of the Ministry of Health of the Russian Federation \"Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)\".","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"0.8"},{"groupId":"OG001","value":"2.4","spread":"3.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Patients With Negative PCR Test for SARS-CoV-2","description":"Number of patients with a negative PCR test result for SARS-CoV-2 on days 6 and 10 of observation. Based on the medical records.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Adverse Events (AEs)","description":"The presence of adverse events. Based on medical records.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Severity of AEs","description":"The intensity (severity) of adverse events. Based on medical records.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Causal Relationship of AEs to the Sudy Drug","description":"The causal relationship to the study drug of adverse events. Based on medical records.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Outcome of AEs","description":"The outcome of adverse events. Based on medical records.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm)","description":"The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in visits 1, 3 and 4 (on days 1 and 6).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.7","spread":"10.4"},{"groupId":"OG001","value":"81.9","spread":"10.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.9","spread":"6.3"},{"groupId":"OG001","value":"74.4","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.6","spread":"6.0"},{"groupId":"OG001","value":"73.2","spread":"5.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute","description":"Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in visits 1, 3 and 4 (on days 1 and 6).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":"1.4"},{"groupId":"OG001","value":"17.2","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"1.2"},{"groupId":"OG001","value":"16.5","spread":"1.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.4","spread":"1.3"},{"groupId":"OG001","value":"16.4","spread":"1.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Changes in Vital Signs: Capillary Blood Oxygen Saturation (SpO2)","description":"Outcome Measure is based on the medical records. The patient's capillary blood oxygen saturation (SpO2) is measured by physician in visits 1, 3 and 4 (on days 1 and 6).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":"0.9"},{"groupId":"OG001","value":"97.8","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":"0.8"},{"groupId":"OG001","value":"98.3","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":"0.8"},{"groupId":"OG001","value":"98.5","spread":"0.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg)","description":"Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in visits 1, 3 and 4 (on days 1 and 6).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"122.1","spread":"9.5"},{"groupId":"OG001","value":"122.1","spread":"9.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.8","spread":"8.3"},{"groupId":"OG001","value":"121.2","spread":"8.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.1","spread":"7.6"},{"groupId":"OG001","value":"121.2","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.9","spread":"6.8"},{"groupId":"OG001","value":"76.8","spread":"7.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":"6.2"},{"groupId":"OG001","value":"76.3","spread":"6.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":"6.0"},{"groupId":"OG001","value":"76.1","spread":"6.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Patients With Clinically Significant Abnormal Laboratory Tests","description":"Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":382},"commonTop":["Increased transaminases","Nausea","Increased blood pressure","Increased C-reactive protein","Itching, cutaneous"]}}}